Later clinical trials with other anti-C5 therapies demonstrated greater improvements in generalized MG (172, 173), resulting in approval of ravulizumab (a long-acting monoclonal antibody against C5) and zilucoplan (a C5-blocking cyclic peptide). This evidence concerns the gene C5 and myasthenia gravis.